Other research analysts have also issued research reports about the stock. Jefferies Financial Group reissued a "hold" rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson restated a "buy" rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a research note on Monday, December 9th. Finally, StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $85.25.
Read Our Latest Stock Analysis on PBH
Shares of PBH opened at $78.72 on Thursday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The company has a market cap of $3.89 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 2.32 and a beta of 0.49. The stock has a fifty day moving average price of $79.25 and a two-hundred day moving average price of $73.04. Prestige Consumer Healthcare has a 52-week low of $57.95 and a 52-week high of $86.36.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting analysts' consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same period last year, the company earned $1.07 earnings per share. The company's revenue was down .9% on a year-over-year basis. Analysts predict that Prestige Consumer Healthcare will post 4.44 EPS for the current fiscal year.
In related news, insider William P'pool sold 8,987 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now directly owns 20,058 shares in the company, valued at approximately $1,641,747.30. The trade was a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares of the company's stock, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,810 shares of company stock valued at $3,187,300. Insiders own 1.60% of the company's stock.
Several hedge funds and other institutional investors have recently modified their holdings of PBH. Boston Trust Walden Corp acquired a new stake in shares of Prestige Consumer Healthcare during the third quarter valued at about $41,785,000. Ariel Investments LLC increased its position in Prestige Consumer Healthcare by 10.7% in the 2nd quarter. Ariel Investments LLC now owns 2,835,203 shares of the company's stock valued at $195,204,000 after acquiring an additional 274,212 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Prestige Consumer Healthcare by 26.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company's stock valued at $90,891,000 after acquiring an additional 272,773 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 9.0% during the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company's stock worth $142,827,000 after purchasing an additional 171,357 shares during the period. Finally, F M Investments LLC bought a new stake in shares of Prestige Consumer Healthcare in the second quarter worth $11,162,000. Institutional investors own 99.95% of the company's stock.
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.